Systemic sclerosis (SSc) is a rare, progressive, debilitating autoimmune disorder characterized by skin fibrosis, systemic inflammation, and vasculopathy that manifests as Raynaud’s disease, skin thickening, and, often, painful digital ulcers. Mortality risks of pulmonary arterial hypertension (PAH), interstitial lung disease (ILD), and renal crisis are high in SSc patients. The only disease-modifying therapies (DMTs) approved for SSc are Boehringer Ingelheim’s Ofev (nintedanib) and Roche / Genentech’s Actemra / RoActemra (tocilizumab), both of which target the SSc-ILD subpopulation and have demonstrated the ability to slow the progressive loss of lung function. The mid-phase SSc pipeline is large and diverse. Although there is tremendous need for additional effective DMTs, drug development in SSc has been historically challenging due to the heterogeneity of SSc patients and the commensurate challenges with trial design.
· How large is the diagnosed SSc population in the United States and EU5, and how will it change over time?
· What is the current treatment landscape in SSc, and how will it change in the next 10 years?
· What do key opinion leaders view as the greatest unmet medical needs in the management of SSc?
· What is the commercial potential of key emerging therapies? How will they fit into the SSc treatment landscape?
Niche & Rare Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.